Several studies showed that activity of down inhibitor bundle is weakened in different painful pathologies as the fibromyalgy or the trigeminal nevralgy.
The purpose of the protocol is to study the working of down inhibitor bundle at patients suffering of neuropathic pain.

Start Date01 Apr 2010

Sponsor / Collaborator

Centre Hospitalier Universitaire de Clermont Ferrand

[+1]

100 Clinical Results associated with Neuropathic Pain therapy(Akaal Pharma Pty Ltd)

100 Translational Medicine associated with Neuropathic Pain therapy(Akaal Pharma Pty Ltd)

100 Patents (Medical) associated with Neuropathic Pain therapy(Akaal Pharma Pty Ltd)

Literatures (Medical) associated with Neuropathic Pain therapy(Akaal Pharma Pty Ltd)

01 Jun 2021·BurnsQ3 · MEDICINE

Prescribing patterns of opioids and adjunctive analgesics for patients with burn injuries

Q3 · MEDICINE

Article

Author: Sarah Rehou ; Shahriar Shahrokhi ; Celine Yeung ; Alex Kiss

PURPOSELarge quantities of analgesics are prescribed to control pain among patients with burn injuries and may lead to chronic use and dependency. This study aimed to determine whether patients are overprescribed analgesics at discharge and to identify factors that influence prescribing patterns.MATERIAL AND METHODSA retrospective review of patient charts (n = 199) between July 1, 2015-2018 were reviewed from a registry at a single burn center. Opioid, neuropathic pain agent, acetaminophen, and ibuprofen quantities given before and at discharge were compared. Linear mixed regression models were used to identify factors that increased the amount of analgesics prescribed.RESULTSOn average, patients were prescribed significantly more analgesics at discharge compared to what was consumed pre-discharge (p < 0.0001). Specifically, on average, providers did not overprescribe the daily dose, but overprescribed the duration of pain medications required. For every increase in percent TBSA, 14 MEQ more opioids, 203 mg more neuropathic pain agents, 843 mg more acetaminophen, and 126 mg more ibuprofen were prescribed (p < 0.05). Surgery was a predictor for higher opioid and neuropathic pain agent prescriptions (p = 0.03), while length of stay was associated with fewer neuropathic pain agents prescribed (p = 0.04). Fewer ibuprofen were given to patients with a history of substance misuse (p = 0.01).CONCLUSIONSThe quantity of analgesics prescribed at discharge varied widely and often prescribed for long durations of time. Standardized prescribing guidelines should be developed to optimize how analgesics are prescribed at discharge.

100 Deals associated with Neuropathic Pain therapy(Akaal Pharma Pty Ltd)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuralgia	Preclinical	AU	Akaal Pharma Pty Ltd.	26 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Neuropathic Pain therapy(Akaal Pharma Pty Ltd)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation